Karus Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Karus Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0490
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Karus Therapeutics Ltd (Karus) is a drug development company that designs and develops cancer therapies. The company offers small molecule drugs with immunotherapy for the treatment of hematological and solid tumors. Its pipeline products include KA2507 and KA2237 inhibitors. Karus’ KA2507 is a highly selective inhibitor of HDAC6 for the treatment of multiple myeloma and inflammatory diseases. The company’s KA2237 is a dual selective inhibitor of P13K for the treatment of solid tumors and hematological cancers. Its development programs offer medical needs in the fields of chronic inflammation, retaining drug design, immunotherapeutic modes, haematological malignancies and solid tumours. Karus is headquartered in Oxford, the UK.

Karus Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Karus Therapeutics Raises US$7 Million In First Tranche Of Series B Financing 10
Partnerships 12
Karus Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 12
Babraham Institute And Karus Therapeutics To Explore PI3 Kinase Inhibitors In Treatment of Inflammatory Diseases 13
Karus Therapeutics Ltd – Key Competitors 14
Karus Therapeutics Ltd – Key Employees 15
Karus Therapeutics Ltd – Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Karus Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Karus Therapeutics Raises US$7 Million In First Tranche Of Series B Financing 10
Karus Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 12
Babraham Institute And Karus Therapeutics To Explore PI3 Kinase Inhibitors In Treatment of Inflammatory Diseases 13
Karus Therapeutics Ltd, Key Competitors 14
Karus Therapeutics Ltd, Key Employees 15

List of Figures
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Karus Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • UniQuest Pty Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary UniQuest Pty Ltd (UniQuest), a subsidiary of The University of Queensland is a commercialization company that offers consultancy services. The company commercializes intellectual property and research outcomes of University of Queensland. It offers services such as eShop, witness, contract r …
  • Nordstrom Inc (JWN):企業の財務・戦略的SWOT分析
    Nordstrom Inc (JWN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Relievant MedSystems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Relievant MedSystems Inc (Relievant) is a medical device company developing new minimally-invasive solutions for the treatment of chronic low back pain (CLBP). The company's Intracept system, a minimally invasive procedure uses radiofrequency energy delivered through a small access tube into …
  • Electricity Generating Authority of Thailand:企業の戦略・SWOT・財務分析
    Electricity Generating Authority of Thailand - Strategy, SWOT and Corporate Finance Report Summary Electricity Generating Authority of Thailand - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Indena SpA:企業の戦略的SWOT分析
    Indena SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Kin and Carta plc (KCT):企業の財務・戦略的SWOT分析
    Kin and Carta plc (KCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Brambles Limited:企業の戦略・SWOT・財務分析
    Brambles Limited - Strategy, SWOT and Corporate Finance Report Summary Brambles Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • NextEra Energy Inc (NEE):企業の財務・戦略的SWOT分析
    NextEra Energy Inc (NEE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • FTS International Services LLC:企業の戦略的SWOT分析
    FTS International Services LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Spark Therapeutics Inc (ONCE):製薬・医療:M&Aディール及び事業提携情報
    Summary Spark Therapeutics Inc (Spark) is a clinical-stage gene therapy company which provides gene therapies for inherited retinal diseases (IRDs), neurodegenerative diseases, as well as liver diseases. Its pipeline products include SPK-RPE65, SPK-CHM, rhonova, LHON, SPK-FIX, SPK-FVIII and SPK-TPP1 …
  • De La Rue Plc (DLAR):企業の財務・戦略的SWOT分析
    De La Rue Plc (DLAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Chaman Lal Setia Exports Ltd:企業の戦略・SWOT・財務分析
    Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report Summary Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Johnson Controls International Plc (JCI):電力:M&Aディール及び事業提携情報
    Summary Johnson Controls International Plc (Johnson Controls) is a diversified technology and multi industrial company. It creates intelligent buildings, integrated infrastructure, efficient energy solutions, and next generation transportation systems. The company provides HVAC equipment, HVAC contr …
  • Chiyoda Corp (6366):企業の財務・戦略的SWOT分析
    Chiyoda Corp (6366) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • PT Bank Bukopin Tbk:企業の戦略・SWOT・財務分析
    PT Bank Bukopin Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Bank Bukopin Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Litha Healthcare Group Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Litha Healthcare Group Ltd (Litha Healthcare), formerly Myriad Medical Holdings Limited, a subsidiary of Endo International plc is a healthcare company that provides its services to public and private hospitals, pharmacies, general, allied practitioners, and government healthcare programmes. …
  • RCS MediaGroup SpA (RCS):企業の財務・戦略的SWOT分析
    RCS MediaGroup SpA (RCS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Yale School of Medicine-製薬・医療分野:企業M&A・提携分析
    Summary Yale School of Medicine (YSM), a subsidiary of Yale University is an educational service provider that offers bio-medical research, education and advanced health care. The center provides degree programs such as public health program, physician associate program, other PhD programs, medical …
  • Industrias Metalurgicas Pescarmona SA:企業の戦略的SWOT分析
    Industrias Metalurgicas Pescarmona SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Natera Inc (NTRA):医療機器:M&Aディール及び事業提携情報
    Summary Natera Inc (Natera), formerly Gene Security Network Inc is a genetic testing and diagnostics company that develops and commercializes non-invasive methods for DNA analysis. The company offers products such as panorama prenatal testing, pre-implantation genetic testing, miscarriage testing, g …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆